FDA approves Celltrion’s subcutaneous Remicade biosimilar for IBD

The US Food and Drug Administration (FDA) has approved Celltrion USA’s Zymfentra (infliximab-dyyb) for the maintenance treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease.